Dramatic Extrahepatic Cholestasis Improvement after Steroid Therapy

Bagus Setyoboedi1,2, Rendi Aji Prihaningtyas1,2, Sjamsul Arief1,2

  • 1Department of Child Health, Dr. Soetomo General Academic Hospital, Surabaya, Indonesia.

Insights

Steroid treatment shows promise in infants with extrahepatic cholestasis potentially leading to biliary atresia. This approach may reduce inflammation and prevent disease progression, offering a new therapeutic avenue.

Area of Science:

  • Pediatric Gastroenterology
  • Hepatology
  • Neonatal Care

Background:

  • Biliary atresia is a significant cause of pediatric liver transplantation.
  • Current treatments like Kasai surgery have limitations.

Observation:

  • A case report details an infant presenting with jaundice, pale stools, and dark urine.
  • Laboratory tests revealed elevated liver enzymes and cholestasis.
  • Cytomegalovirus (CMV) infection was noted concurrently.

Findings:

  • Percutaneous liver biopsy confirmed extrahepatic cholestasis.
  • Treatment with steroids and ursodeoxycholic acid led to significant clinical and biochemical improvement.
  • Improvements included reduced bilirubin levels, normalized liver enzymes, and increased hemoglobin.

Implications:

  • Steroid administration may mitigate biliary system inflammation in extrahepatic cholestasis.
  • This treatment could potentially halt the progression to biliary atresia.
  • Further research into steroid therapy for biliary atresia is warranted.

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
92
Chronic Pancreatitis II: Collaborative Care01:29

Chronic Pancreatitis II: Collaborative Care

The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
51
Chronic Bowel Disorders: Introduction01:17

Chronic Bowel Disorders: Introduction

Chronic bowel diseases are a group of long-term conditions affecting the digestive tract, characterized by inflammation and damage to the gut lining. These conditions primarily include irritable bowel syndrome and inflammatory bowel disease.
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
374
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
119
Hepatic Drug Excretion: Enterohepatic Cycling01:17

Hepatic Drug Excretion: Enterohepatic Cycling

Enterohepatic cycling involves the active secretion of drugs and their metabolites into the bile via transporters in the canalicular membrane of hepatocytes. This secretion is an integral part of the digestive process, releasing these substances into the gastrointestinal (GI) tract.
Post-release drugs and metabolites can be reabsorbed into the body from the intestine. For conjugated metabolites like glucuronides, reabsorption requires enzymatic hydrolysis by intestinal microflora. This...
886